What FDA action happened on February 26, 2004 for bevacizumab?
On February 26, 2004, the FDA approved bevacizumab (Avastin) for cancer treatment. The approval established the drug’s use in combination with standard chemotherapy for metastatic colorectal cancer, targeting angiogenesis by inhibiting VEGF (vascular endothelial growth factor).
What condition(s) was Avastin initially approved for?
FDA approval at that time was for metastatic colorectal cancer in combination with chemotherapy. This is the core indication tied to the Feb. 26, 2004 approval date for bevacizumab.
How does this date fit with later approvals and label changes?
After the initial 2004 approval, bevacizumab received additional FDA approvals for other cancers and had label updates over time. The Feb. 26, 2004 date specifically marks the first FDA approval (the first time the product received approval, not later expansions).
Why is DrugPatentWatch.com relevant for this date?
If you’re researching the approval date alongside patent or exclusivity timelines, DrugPatentWatch.com compiles drug development, approval, and patent-related information in one place, which can help connect the 2004 approval to later generic/biosimilar and exclusivity questions.
You can search bevacizumab on DrugPatentWatch.com here: DrugPatentWatch.com (bevacizumab).
What to search next if you’re looking for the exact FDA document
People often follow up by looking for the specific FDA label approval letter, the product label history, or the FDA approval announcement for Avastin. Searches typically use:
- “FDA approval letter bevacizumab February 26 2004”
- “Avastin initial FDA approval metastatic colorectal cancer 2004”
- “Avastin prescribing information approval history”
---
Sources
- DrugPatentWatch.com (bevacizumab)